Columbia Threadneedle Investments · 1 month ago
Biotech Analyst, Seligman Investments
Columbia Threadneedle Investments is a reputable asset manager with over $654 billion in assets under management, seeking a Biotech/Pharmaceutical Analyst to join their Healthcare Fund. The role involves conducting comprehensive research and analysis in the biotech and pharmaceutical sectors to generate investment recommendations and support the fund's objectives.
FinanceConsultingAsset ManagementFinancial Services
Responsibilities
Biotech and pharmaceutical public equity coverage and research of both commercial and development stage drug candidates
Conduct rigorous scientific, clinical, statistical, manufacturing, patent, regulatory due diligence - quickly distilling what information may impact investment thesis
Generate investment recommendations: thesis, risk-reward, supporting evidence, and catalysts
Build and maintain therapeutic class, disease area, regulatory precedents databases
Drive valuation conclusions through revenue builds, financial models, comp sheets
Continually refine thesis and research processes
Communicate effectively research and new developments in a timely manner
Qualification
Required
5+ years in the biotechnology/ pharmaceutical sector either in clinical, scientific, financial services, or industry capacity
2+ years of experience as a buyside investment analyst covering biotech/ pharmaceuticals
Proven ability to interpret clinical and scientific data and translating findings into investment implications and recommendations
Strong financial modeling, valuation, and analytical abilities
Preferred
Experience with private investments and derivatives
Experience with advanced data analysis/ coding/ modeling
Advanced degree (Doctorate/ Masters)
Benefits
Variable pay in the form of bonus, commissions, and/or long-term incentives depending on the role
Vacation time
Sick time
401(k)
Health, dental and life insurances
Company
Columbia Threadneedle Investments
Columbia Threadneedle Investments is an asset management firm.
Funding
Current Stage
Late StageRecent News
2026-07-17
2026-07-14
Company data provided by crunchbase